Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company at the forefront of developing innovative bi-functional fusion proteins. These unique proteins represent a new class of biologic medicine aimed at treating patients with cancer and autoimmune diseases. Shattuck's proprietary Agonist Redirected Checkpoint (ARC®) platform is designed to inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic, a groundbreaking approach in the biotechnology field.
The company's lead product candidate, SL-172154 (SIRPα-Fc-CD40L), is engineered to block the CD47 immune checkpoint and activate the CD40 pathway simultaneously. Currently, SL-172154 is in multiple Phase 1 clinical trials targeting various cancers, including platinum-resistant ovarian cancer and acute myeloid leukemia (AML). Another promising candidate, SL-279252 (PD1-Fc-OX40L), is being developed in collaboration with Takeda Pharmaceuticals and is also in Phase 1 trials.
Shattuck Labs recently embarked on an exciting collaboration with Ono Pharmaceutical to develop bifunctional fusion proteins for autoimmune and inflammatory diseases. This partnership includes a significant financial package with potential milestone payments and royalties, reinforcing Shattuck's strong financial condition and innovative capabilities. Additionally, the company's proprietary gamma delta T cell engager platform, GADLEN™, promises to bridge gamma delta T cells to tumor antigens, offering new hope for cancer treatment.
Recent achievements include rapid enrollment in clinical trials and the FDA's orphan drug designation for SL-172154, highlighting the urgent need for new AML treatments. Shattuck is also actively participating in several high-profile conferences, sharing their latest research and clinical progress. The company is headquartered in Austin, Texas, and Durham, North Carolina, and continues to leverage its scientific expertise to address unmet medical needs.
- Core Business: Development of bi-functional fusion proteins for cancer and autoimmune diseases.
- Recent Achievements: FDA orphan drug designation for SL-172154, collaboration with Ono Pharmaceutical.
- Current Projects: Phase 1 trials for SL-172154 and SL-279252, development of GADLEN™ platform.
- Financial Condition: Strong financial backing with potential milestone payments from partnerships.
- Partnerships: Collaborations with Ono Pharmaceutical and Takeda Pharmaceuticals.
The press release from Shattuck Labs (NASDAQ: STTK) highlights preclinical findings from the GADLEN platform presented at the AACR Annual Meeting. The CD20-targeted GADLEN demonstrated a rapid and efficient ability to deplete over 99% of human B cells in humanized mouse models and non-human primates without significant toxic effects. This promising data suggests potential for treating antibody-mediated autoimmune diseases. The GADLEN compound was well-tolerated at doses up to 25 mg/kg, indicating a favorable safety profile compared to existing T cell engagers.
Shattuck Labs, Inc. (NASDAQ: STTK) announced participation in two key investor conferences in March 2023. The Cowen 43rd Annual Health Care Conference will feature Dr. Lini Pandite discussing innovative oncology approaches on March 6 at 9:10 a.m. ET. On March 13, Dr. Taylor Schreiber will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference at 2:00 p.m. ET. Both events will be live-streamed and later archived on the company's website. Shattuck Labs is focused on advancing bi-functional fusion proteins targeting cancer and autoimmune diseases, with several ongoing Phase 1 trials, including its lead program SL-172154.
Shattuck Labs reported significant progress in clinical trials and announced key management changes. The Phase 1B trial of SL-172154 with mirvetuximab soravtansine in platinum-resistant ovarian cancer has begun enrollment. Initial data from this trial and others involving SL-172154 is expected in mid to late 2023. However, the company discontinued the SL-279252 program after failing to meet efficacy thresholds in Phase 1 trials. Financially, Shattuck reported a net loss of $25.4 million for Q4 2022, compared to a net income of $7.8 million a year prior, with R&D expenses rising to $82.9 million for the year. The company forecasts its cash reserves will sustain operations into H2 2024.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company, will report its fourth quarter and full year 2022 financial results on February 23, 2023. The company specializes in bi-functional fusion proteins for cancer and autoimmune diseases, utilizing its proprietary Agonist Redirected Checkpoint (ARC®) platform. The lead program, SL-172154, is in multiple Phase 1 trials, aiming to block the CD47 checkpoint while activating the CD40 pathway. CEO Taylor Schreiber and other executives will present the results during a conference call at 4:45 p.m. ET, with a live webcast available for investors.
Shattuck Labs, Inc. (NASDAQ: STTK) has announced participation in the SVB Securities Global Biopharma Conference, scheduled for February 13-16, 2023. The company specializes in developing bi-functional fusion proteins aimed at treating cancer and autoimmune diseases. Its lead program, SL-172154, is currently in multiple Phase 1 trials, targeting CD47 immune checkpoints while activating the CD40 pathway. Additionally, Shattuck is advancing its GADLEN™ platform, designed to connect gamma delta T cells with tumor antigens. The company is focused on transparent investor communication and compliance with regulatory obligations.
Shattuck Labs, Inc. (NASDAQ: STTK) provided a corporate update on January 9, 2023, emphasizing its focus on clinical execution for 2023. Key achievements in 2022 included the advancement of SL-172154 through various clinical trials for platinum-resistant ovarian cancer and its combination therapies. The company plans several critical data readouts in 2023, including results for SL-172154 in acute myeloid leukemia and higher-risk myelodysplastic syndromes. Shattuck ended Q3 2022 with approximately $185.1 million in cash, which is projected to sustain operations into the second half of 2024.
Shattuck Labs (NASDAQ: STTK) reported its Q3 2022 financial results and significant clinical advancements. The company completed enrollment in a Phase 1 trial for SL-172154 in platinum-resistant ovarian cancer, with complete data expected mid-2023. Additionally, the first patient was dosed in a combination trial with liposomal doxorubicin. Despite a cash position of $185.1 million, Shattuck incurred a net loss of $24.6 million for the quarter, increasing from $17.4 million YoY. The company anticipates its cash will fund operations into H2 2024.
Shattuck Labs, Inc. (NASDAQ: STTK) announced preclinical proof-of-concept data for its GADLEN platform at the 2022 SITC Annual Meeting. The data revealed two GADLEN candidates targeting CD20 and B7-H3, which enhanced the ability of γδT cells to kill tumor cells. These bispecific engagers showed a selective cytotoxic effect against B7-H3 expressing tumors and CD20 expressing lymphoma cells, indicating potential applications in treating various cancers. The platform's modularity allows for targeting specific tumor antigens, which could advance cancer therapies significantly.
Shattuck Labs (NASDAQ: STTK) announced its participation in three investor conferences in November and December 2022. CEO Dr. Taylor Schreiber will present at the Cowen’s 6th Annual IO Next Summit on November 11 and the Evercore ISI HealthCONx Conference on November 29. CFO Andrew Neill will present at the Piper Sandler Healthcare Conference on December 1. The company focuses on developing bi-functional fusion proteins to treat cancer and autoimmune diseases through its proprietary ARC® platform, which targets immune checkpoints and pathways simultaneously.
Shattuck Labs (NASDAQ: STTK) will report its Q3 2022 financial results on November 8, 2022, at 4:30 p.m. ET, during a conference call led by CEO Taylor Schreiber. Experts anticipate insights into the company's innovative bi-functional fusion proteins aimed at treating cancer and autoimmune diseases. Currently, the SL-172154 and SL-279252 programs are in Phase 1 trials, utilizing Shattuck's proprietary ARC® platform. Investors can listen to the live webcast on Shattuck's website.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
What is Shattuck Labs, Inc.'s core business?
What are the main product candidates of Shattuck Labs?
What is the ARC® platform?
Who are Shattuck Labs' key partners?
Where is Shattuck Labs headquartered?
What is SL-172154?
What recent achievements has Shattuck Labs made?
What is the GADLEN™ platform?
What financial condition is Shattuck Labs in?
What are some upcoming events for Shattuck Labs?
